Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217443 | 1.00 | ALDH1A1 (0.55) | ALDH1A1LMNAHIF1ATSHRPRKDC | |
| SCHEMBL27536636 | 0.88 | ALDH1A1 (0.56) | ALDH1A1LMNAHIF1ATSHRPRKDC | |
| SCHEMBL6787925 | 0.86 | MAPT (0.53) | ALDH1A1LMNAHIF1ATSHRPTGS2 | |
| SCHEMBL2444961 | 0.85 | HIF1A (0.55) | ALDH1A1LMNAHIF1ATSHRPRKDC | |
| SCHEMBL27602621 | 0.85 | ALDH1A1 (0.51) | ALDH1A1LMNAHIF1ATSHRPTGS2 | |
| SCHEMBL2370538 | 0.83 | NPC1 (0.50) | ALDH1A1LMNAPTGS2PTGS1MAPT | |
| SCHEMBL28456821 | 0.83 | ALDH1A1 (0.51) | ALDH1A1LMNAHIF1ATSHRPRKDC | |
| SCHEMBL5332118 | 0.82 | ALDH1A1 (0.54) | ALDH1A1LMNATSHRPTGS2PTGS1 | |
| SCHEMBL23053215 | 0.81 | ALDH1A1 (0.49) | ALDH1A1LMNAHIF1ATSHRPRKDC | |
| SCHEMBL11061699 | 0.81 | ALDH1A1 (0.49) | ALDH1A1LMNAHIF1ATSHRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276732-B1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | DOMPE PHA R MA SPA RES & MFG (IT) | 2007-09-26 | — | — | EP | disclosed |
| US-7217707-B2 | Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation | DOMPE S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | MMP8, CXCL8, HCAR2 | ALDH1A1 391/4885LMNA 2262/4885HIF1A 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.